Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Cancer Chemotherapy

Background:

• Medulloblastoma is the most prevalent childhood brain tumor.
• Management strategies have significantly evolved over the last two decades.
• Chemotherapy is now a cornerstone in treating most medulloblastoma patients.

Purpose of the Study:

• To review the role and efficacy of chemotherapy in medulloblastoma management.
• To assess the impact of chemotherapy timing and dosage on patient outcomes.
• To explore current treatment challenges and future directions, particularly for infants.

Main Methods:

• Review of prospective randomized trials and institutional studies.
• Analysis of chemotherapy regimens, including adjuvant and neoadjuvant approaches.
• Evaluation of outcomes based on disease extent, patient age, and treatment sequencing.

Main Results:

• Adjuvant chemotherapy with radiation improves outcomes for newly diagnosed medulloblastoma, particularly for extensive disease (up to 85% event-free survival).
• Pre-radiation chemotherapy has not shown survival benefits and may lead to poorer outcomes.
• High-dose chemotherapy with stem cell rescue shows promise for infants with medulloblastoma.

Conclusions:

• Chemotherapy, especially when used adjunctively with radiotherapy, is vital for improving medulloblastoma treatment outcomes.
• The optimal timing and role of chemotherapy in relation to radiation therapy require further investigation.
• Treatment for infants with medulloblastoma remains challenging, with ongoing research into intensive chemotherapy approaches.